Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-24-144499
Filing Date
2024-05-22
Accepted
2024-05-22 08:55:13
Documents
2

Document Format Files

Seq Description Document Type Size
1 424B5 d818275d424b5.htm 424B5 462189
2 GRAPHIC g818275g83k05.jpg GRAPHIC 26495
  Complete submission text file 0001193125-24-144499.txt   499736
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-262551 | Film No.: 24971722
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)